Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
Holding HAE?
Track your performance easily
HAE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$70.25 - $97.97
Previous Close$88.46
Volume602.15K
Average Volume (3M)623.05K
Market Cap
$4.44B
Enterprise Value$5.37B
Total Cash (Recent Filing)$299.28M
Total Debt (Recent Filing)$1.22B
Price to Earnings (P/E)36.7
Beta1.15
Next Earnings
Feb 11, 2025EPS Estimate
$1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.41
Shares Outstanding50,223,887
10 Day Avg. Volume891,607
30 Day Avg. Volume623,046
Standard Deviation0.11
R-Squared0.02
Alpha-0.00561
Financial Highlights & Ratios
Price to Book (P/B)4.85
Price to Sales (P/S)3.13
Price to Cash Flow (P/CF)21.80
P/FCF Ratio27.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.94
Enterprise Value/Gross Profit7.76
Enterprise Value/Ebitda18.96
Forecast
1Y Price Target
$115.50Price Target Upside30.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Haemonetics News
PremiumCompany Announcements
Haemonetics’ Q2 2025 Earnings Show Strong GrowthBulls Say, Bears Say
Bulls Say
Market ExpansionAcquiring Vivasure Medical could complement HAE's existing product offerings and drive growth in a $300M market segment.
Product InnovationThe PerQseal device developed by Vivasure Medical is likely to receive FDA approval, which could benefit HAE.
Strategic InvestmentHAE invested €30M in Vivasure Medical, indicating a strategic interest in innovative medical technologies.
Bears Say
Investor ConfidenceHAE shares are down ~15% since fiscal Q1 results in early August as investors’ confidence in Street numbers was shaken.
Revenue GuidanceManagement dropped the inorganic revenue contribution by 100 bp in the guide after disappointing on this front in F2Q.
Sales DeclinePlasma sales declined 3% organic in F2Q25 similar to the 3% organic decline in F1Q25 given the CSL transition.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
HAE FAQ
What was Haemonetics Corp.’s price range in the past 12 months?
Haemonetics Corp. lowest stock price was $70.25 and its highest was $97.97 in the past 12 months.
What is Haemonetics Corp.’s market cap?
Currently, no data Available
When is Haemonetics Corp.’s upcoming earnings report date?
Haemonetics Corp.’s upcoming earnings report date is Feb 11, 2025 which is in 76 days.
How were Haemonetics Corp.’s earnings last quarter?
Haemonetics Corp. released its earnings results on Nov 07, 2024. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.073 by $0.047.
Is Haemonetics Corp. overvalued?
According to Wall Street analysts Haemonetics Corp.’s price is currently Undervalued.
Does Haemonetics Corp. pay dividends?
Haemonetics Corp. does not currently pay dividends.
What is Haemonetics Corp.’s EPS estimate?
Haemonetics Corp.’s EPS estimate is $1.18.
How many shares outstanding does Haemonetics Corp. have?
Haemonetics Corp. has 50,223,890 shares outstanding.
What happened to Haemonetics Corp.’s price movement after its last earnings report?
Haemonetics Corp. reported an EPS of $1.12 in its last earnings report, beating expectations of $1.073. Following the earnings report the stock price went up 10.709%.
Which hedge fund is a major shareholder of Haemonetics Corp.?
Among the largest hedge funds holding Haemonetics Corp.’s share is Royce & Associates LLC. It holds Haemonetics Corp.’s shares valued at 97M.
---
Haemonetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$115.50 (30.46% Upside)
$115.50 (30.46% Upside)
Blogger Sentiment
Bullish
HAE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 7.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.95%
12-Months-Change
Fundamentals
Return on Equity
13.97%
Trailing 12-Months
Asset Growth
25.55%
Trailing 12-Months
Company Description
Haemonetics Corp.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.
---
HAE Earnings Call
Q2 2024
0:00 / 0:00
---
HAE Stock 12 Month Forecast
Average Price Target
$115.50
▲(30.46% Upside)
Technical Analysis
Best Analysts Covering HAE
1 Year
1 Year Success Rate
26/42 ratings generated profit
1 Year Average Return
+10.66%
reiterated a buy rating 20 days ago
Copying Michael Petusky's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +10.66% per trade.
---